Insider Selling: Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Sells $273,455.00 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric M. Dube sold 11,375 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $24.04, for a total transaction of $273,455.00. Following the completion of the sale, the chief executive officer now owns 419,173 shares of the company’s stock, valued at approximately $10,076,918.92. The trade was a 2.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Travere Therapeutics Price Performance

Shares of TVTX stock opened at $22.91 on Friday. The company has a market capitalization of $1.79 billion, a PE ratio of -5.04 and a beta of 0.72. The firm has a fifty day simple moving average of $19.22 and a 200-day simple moving average of $16.10. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. Travere Therapeutics, Inc. has a twelve month low of $5.12 and a twelve month high of $25.29.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on TVTX shares. Barclays boosted their target price on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 1st. Wells Fargo & Company upgraded shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $9.00 to $27.00 in a research note on Monday, October 21st. Scotiabank boosted their price objective on shares of Travere Therapeutics from $27.00 to $32.00 and gave the stock a “sector outperform” rating in a research note on Wednesday. HC Wainwright boosted their price objective on shares of Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, January 15th. Finally, Piper Sandler boosted their price objective on shares of Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a research note on Thursday, November 14th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $27.77.

Institutional Trading of Travere Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Aigen Investment Management LP acquired a new stake in Travere Therapeutics in the third quarter valued at $170,000. Oppenheimer & Co. Inc. acquired a new stake in Travere Therapeutics in the third quarter valued at $673,000. FMR LLC raised its holdings in Travere Therapeutics by 27.5% in the third quarter. FMR LLC now owns 147,416 shares of the company’s stock valued at $2,062,000 after acquiring an additional 31,772 shares in the last quarter. Two Sigma Advisers LP raised its holdings in Travere Therapeutics by 30.2% in the third quarter. Two Sigma Advisers LP now owns 720,400 shares of the company’s stock valued at $10,078,000 after acquiring an additional 167,100 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Travere Therapeutics by 3.9% in the third quarter. Geode Capital Management LLC now owns 1,731,045 shares of the company’s stock valued at $24,222,000 after acquiring an additional 64,744 shares in the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.